Hospital Corporation of China Ltd

Hospital Corporation of China Ltd maintains a liquidity profile with a current ratio of 1.62, indicating moderate short-term liquidity. The company's debt-to-equity ratio is 2.1, suggesting a relatively high leverage position. Despite this, the company holds cash and equivalents of CNY 665.67 million, which is partially offset by long-term debt of CNY 1.06 billion, resulting in a net cash position that is negative. In terms of profitability, the company's return on equity (ROE) is 27.15%, which is significantly higher than the median ROE for the Healthcare Facilities & Services industry. The return on assets (ROA) is 5.29%, also above the industry median, indicating efficient use of assets to generate profit. The company's revenue is primarily concentrated in the domestic market, with no disclosed international operations. The three business segments—general hospital services, hospital management services, and pharmaceutical sales—each contribute to the overall revenue, though the exact distribution is not specified in the latest financial data. Looking at the growth trajectory, the company's revenue has shown a positive trend, with a recent annual revenue of CNY 1.47 billion. The outlook for the current fiscal year indicates continued growth, supported by the expansion of hospital services and management operations. The risk assessment highlights a medium liquidity risk, primarily due to the high debt-to-equity ratio and the negative net cash position. The dilution risk is assessed as low, with no immediate pressure from share issuance or dilution events. The company has not disclosed any significant dilution sources in recent filings. Recent events include the company's continued focus on expanding its hospital management services and pharmaceutical sales. No major regulatory or operational disruptions have been reported in the latest filings or transcripts.